-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vilobelimab in Multiple Organ Failure (Multiple Organ Dysfunction Syndrome)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vilobelimab in Multiple Organ Failure (Multiple Organ Dysfunction Syndrome) Drug Details: Vilobelimab (Gohibic) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vilobelimab in Granulomatosis with Polyangiitis (Wegener’s Granulomatosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vilobelimab in Granulomatosis with Polyangiitis (Wegener's Granulomatosis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vilobelimab in Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vilobelimab in Microscopic Polyangiitis (MPA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vilobelimab in Microscopic Polyangiitis (MPA) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vilobelimab in Microscopic Polyangiitis (MPA) Drug Details: Vilobelimab (Gohibic) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMP-019 in Allergies
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMP-019 in Allergies report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AMP-019 in Allergies Drug Details:Epinephrine is under development for the treatment of allergic reactions,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JMKX-1899 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JMKX-1899 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.JMKX-1899 in Non-Small Cell Lung Cancer Drug Details:JMKX-1899 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNT-211 in Testicular Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Testicular Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BNT-211 in Testicular CancerDrug Details:BNT-211 is under development for the treatment of multiple...
-
Sector Analysis
Indonesia Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2028
Indonesia Defense Market Report Overview The Indonesian defense budget is $8.8 billion in 2023 and is expected to grow at a CAGR of more than 2% from 2024 to 2028. The increase in budget is primarily driven by the need to upgrade the country's existing arsenal of armed forces, its participation in peacekeeping missions, and its territorial dispute with neighboring regions. Indonesia Defense Market Outlook, 2023-2028 ($ Billion) Buy Full Report to Gain More Information about the Indonesia Defense Market...
-
Product Insights
Therapeutic Drug Monitoring Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Therapeutic Drug Monitoring Pipeline Market Report Overview Therapeutic drug monitoring tests include reagents and test kits intended to measure different types of therapeutic drugs from samples ranging from serum/blood, urine, hair and sweat. The therapeutic drug monitoring pipeline market research report provides comprehensive information about the Therapeutic drug monitoring pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Key Segments ·      Immunosuppressant Therapeutic Drug Monitoring...
-
Company Profile
InflaRx – Company Profile
InflaRx NV (InflaRx) is a clinical-stage biopharmaceutical company that develops therapies in the field of acute and chronic inflammation. Its pipeline products include INF904, IFX002 and vilobelimab among others. The company offers the development of monoclonal antibodies targeting activation products of the complement system for application in threatening inflammatory diseases and others drug indications. InflaRx operates in various research and development programs in the life science sectors. The company offers antibodies that are able to fulfill requirements determined by InflaRx...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IFx-Hu20
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry IFx-Hu20 Drug Details IFx-Hu20 is under development for the treatment of cutaneous melanoma, Merkel...